Sexual Dysfunction as a Hormone Indicator
Sexual health complaints — decreased libido, erectile dysfunction, vaginal dryness, painful intercourse, and orgasmic dysfunction — are among the most common presenting complaints in hormone practices. They are also among the most sensitive and impactful. Addressing sexual health effectively builds patient loyalty, generates strong referrals, and significantly improves quality of life for a population that is routinely dismissed by conventional providers.
Erectile Dysfunction: The Vascular-Hormonal Connection
Erectile dysfunction (ED) is a complex condition with vascular, neurological, hormonal, and psychological components — often interacting. The hormonal evaluation of ED includes: total and free testosterone, estradiol, prolactin (elevated prolactin causes both low libido and ED), thyroid function, and fasting glucose (diabetes is the leading organic cause of ED). ED is also recognized as an independent cardiovascular risk marker — a thorough vascular assessment is clinically appropriate in all ED patients.
PDE5 Inhibitors: Clinical Prescribing Pearls
Sildenafil (Viagra) and tadalafil (Cialis) are the cornerstone pharmacological treatments for ED. Daily low-dose tadalafil (2.5–5mg) is increasingly preferred for patients requiring consistent effect — it also has benefits for lower urinary tract symptoms. Compounded sildenafil troches (dissolvable lozenges) offer faster onset and allow dosing flexibility. Understand contraindications (nitrate use is absolute), drug interactions, and the importance of addressing underlying cardiovascular and hormonal causes rather than relying on PDE5 inhibitors alone.
Low Libido in Women: The Testosterone Gap
Female sexual interest/arousal disorder (FSIAD) — the clinical term for low sexual desire in women — is dramatically undertreated. Testosterone plays a critical role in female libido, and its decline with age (and after oophorectomy) is directly linked to loss of sexual interest. Low-dose testosterone therapy for women has strong evidence for improving libido and is endorsed by the International Society for Sexual Medicine. Lack of FDA approval should not prevent appropriate clinical use with proper informed consent.
Genitourinary Syndrome of Menopause (GSM)
Vaginal atrophy, dryness, painful intercourse (dyspareunia), and recurrent UTIs in peri- and post-menopausal women are caused by hypoestrogenism — and are collectively termed GSM. Local vaginal estrogen (cream, ring, or suppository) is highly effective, has minimal systemic absorption, and is safe even in women with a history of breast cancer per current guidelines. Ospemifene (oral SERM) is an oral alternative for patients who prefer not to use topical estrogen.
Psychological and Relationship Factors
Sexual dysfunction is rarely purely biological. Stress, relationship conflict, body image, trauma history, and mental health disorders all profoundly affect sexual function. A brief psychosexual history at intake — and willingness to refer to sex therapists or mental health professionals when indicated — demonstrates a holistic approach that patients deeply appreciate. The best sexual health outcomes involve addressing the whole person.